A Study to Evaluate Treatment Satisfaction With Erenumab in Participants With Migraine

Summary

The main purpose of this study is to evaluate the effect of erenumab on medication-specific treatment satisfaction.

Timeline

Start

2021-06-11

Primary completion

2023-09-28

Completion

2023-09-28

Outcome

Mixed primary results

registry Erenumab QM: Continued SoC; p < 0.001; Least squares mean (LSM) 40.72 (95% CI 36.05 to 45.39) NCT04825678 ↗

registry Erenumab QM: Discontinued SoC; p = 0.058; LSM 30.84 (95% CI -1.30 to 62.98) NCT04825678 ↗

registry Erenumab QM: EM; p < 0.001; LSM 37.87 (95% CI 28.62 to 47.12) NCT04825678 ↗

registry Erenumab QM: CM; p < 0.001; LSM 43.25 (95% CI 38.06 to 48.44) NCT04825678 ↗

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Erenumab	Monoclonal antibody	—	Subcutaneous

Indications